Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


MHRA approves Veoza (fezolinetant) to treat vasomotor symptoms associated with menopause – Astellas

Written by | 23 Dec 2023 | Obstetrics & Gynaecology

Veoza (Veozah in the US), also known as fezolinetant, from Astellas, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) after receiving similar approval in the US back in May 2023.

Menopausal hot flushes are experienced by up to 80% of women going through menopause, and can vary from a few seconds of feeling overheated to significant sweating and discomfort that can disrupt sleep or affect their ability to work, especially for women working in thermal environments. Veoza works by blocking a protein in the brain called neurokinin-3, which plays an important role in regulating body temperature in menopausal women.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.